Substitutions in Nef That Uncouple Tetherin and SERINC5 Antagonism Impair Simian Immunodeficiency Virus Replication in Primary Rhesus Macaque Lymphocytes.
Article in Journal of virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 62% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
4 authors at 1 institution in 1 country.
Sanath Kumar JanakaDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Brian J SnowDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.ORCID 0000-0002-7569-636X
Ryan T BehrensDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.ORCID 0000-0001-5761-9056
David T EvansDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.ORCID 0000-0003-2498-6292
University of Wisconsin–Madison · US
Funding
WNPRC Supplemental Request for Nonhuman Primate Enclosures to Equip HIV/AIDS-Related Research FacilitiesP51OD011106 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI Dorota A. Grejner-Brzezinska · 2012 to 2026
$150.7M
BIOTECHNOLOGY TRAINING PROGRAMT32GM008349 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI FOX, BRIAN G · 1989 to 2019
$22.5M
Biotechnology Training ProgramT32GM135066 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI SCOTT M. COYLE, BRIAN G FOX · 2020 to 2026
$7.0M
Sustained antibody delivery for durable suppression of immunodeficiency virus replicationR01AI121135 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI David T Evans · 2015 to 2026
$6.9M
KIR and MHC Class I Immunogenetics in SIV InfectionR37AI095098 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI David T Evans · 2019 to 2026
$5.6M
Assessing ADCC and Fc-mediated Protection against HIVR01AI148379 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI EVANS, DAVID T, FINZI, ANDRES · 2019 to 2023
$3.8M
Harnessing adaptive NK cell transfer to deplete viral reservoirsR01AI161816 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI BARKER, EDWARD, EVANS, DAVID T · 2021 to 2025
$3.8M
Tethering lentiviral restriction to Fc-mediated antibody responsesR01AI155163 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI EVANS, DAVID T · 2020 to 2024
$3.2M
KIR and MHC Class I Immunogenetics in SIV InfectionR01AI095098 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI EVANS, DAVID T · 2012 to 2016
$2.7M
Lentiviral Resistance to TetherinR01AI098485 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI EVANS, DAVID T · 2012 to 2016
$2.2M
HHS | National Institutes of Health (NIH) AI095098HHS | National Institutes of Health (NIH) AI098485HHS | National Institutes of Health (NIH) AI121135HHS | National Institutes of Health (NIH) AI148379HHS | National Institutes of Health (NIH) AI155163HHS | National Institutes of Health (NIH) AI161816HHS | National Institutes of Health (NIH) OD011106NIAID NIH HHS R01 AI095098NIAID NIH HHS R01 AI098485NIAID NIH HHS R01 AI121135NIAID NIH HHS R01 AI148379NIAID NIH HHS R01 AI155163NIAID NIH HHS R01 AI161816NIAID NIH HHS R37 AI095098NIGMS NIH HHS T32 GM008349NIGMS NIH HHS T32 GM135066NIH HHS P51 OD011106
6 · The paper itself
Abstract
Most simian immunodeficiency viruses (SIVs) use Nef to counteract restriction by the tetherin proteins of their nonhuman primate hosts. In addition to counteracting tetherin, SIV Nef has a number of other functions, including the downmodulation of CD3, CD4, and major histocompatibility complex class I (MHC I) molecules from the surface of SIV-infected cells and the enhancement of viral infectivity by preventing the incorporation of SERINC5 into virions. Although these activities require different surfaces of Nef, they can be difficult to separate because of their dependence on similar interactions with AP-1 or AP-2 for clathrin-mediated endocytosis. We previously observed extensive overlap of the SIV Nef residues required for counteracting tetherin and SERINC5. Here, we define substitutions in Nef that separate anti-tetherin activity from SERINC5 antagonism and other activities of Nef. This information was used to engineer an infectious molecular clone of SIV (SIV
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Substitutions in Nef That Uncouple Tetherin and SERINC5 Antagonism Impair Simian Immunodeficiency Virus Replication in Primary Rhesus Macaque Lymphocytes. · full record | OpenQuestion